The government has signaled its hard stance on invoking more compulsory licenses, this with the department of industrial policy and promotion (DIPP) listing three anti-cancer drugs as next compulsory licensing candidates. The industry has mixed views on it, reports CNBC-TV18's Archana Shukla.
first published: Jan 25, 2013 07:59 pm
A collection of the most-viewed Moneycontrol videos.
US Iran War Update: US Military Buildup in Middle East | Trump Prepares for Strike Soon? | Explained
Nifty breaks 3-day gains amid geopolitical tensions | Closing Bell
HDFC Securities Reli Discusses Impact of Tighter Bank Financing On Capital mkt Stocks
PL Capital's Amit Anwani Explains Why Some Power Equipment Maker Stocks Are a Good Investment Bet
